Supporting Information

Asnovolins A–G, Spiromeroterpenoids, as Suppressing Agents of the Fibronectin Expression, from the Fungus *Aspergillus novofumigatus*.

Kazuki Ishikawa,[†] Fumiaki Sato,[†] Takeshi Itabashi,[†] Hiroshi Wachi,[†] Hisashi Takeda,[†] Digo Wakana,[†] Takashi Yaguchi,[‡] Ken-ichi Kawai,[†] and Tomoo Hosoe[†]

[†]Department of Organic Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa, Tokyo, Japan. [‡]Medical Mycology Research Center (MMRC), Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan.

#Address correspondence to Tomoo Hosoe, hosoe@hoshi.ac.jp

Table of Contents

Supporting Figure S1–6

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOESY (400 MHz, CDCl₃) spectra of asnovolin A (**1**) Supporting Figure S7–12

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOE (400 MHz, CDCl₃) spectra of asnovolin B (**2**) Supporting Figure S13–18

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOE (400 MHz, CDCl₃) spectra of asnovolin C (**3**) Supporting Figure S19–24

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOESY (400 MHz, CDCl₃) spectra of asnovolin D (**4**) Supporting Figure S25–30

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOESY (400 MHz, CDCl₃) spectra of asnovolin E (**5**) Supporting Figure S31–36

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOESY (400 MHz, CDCl₃) spectra of asnovolin F (**6**) Supporting Figure S37–42

¹H NMR, ¹³C NMR, HSQC, HMBC, ¹H-¹H COSY, NOESY (400 MHz, CDCl₃) spectra of asnovolin G (**7**) Supporting Figure S43

```
Comparison of CD spectrum of asnovolins A–E (1–5)
```

Supporting Figure S44

```
Key 2D-NMR correlations for asnovolins B, D, E and G (2, 4, 5 and 7)
```

Supporting Figure S45

Key NOESY correlations of asnovolins B, D, E and G (2, 4, 5 and 7)

Supporting Figure S46

Putative biosynthesis pathway of asnovolins.



Figure S1. ¹H NMR (400 MHz, CDCl₃) spectrum of asnovolin A (**1**).



Figure S2. ¹³C NMR (100 MHz, $CDCI_3$) spectrum of asnovolin A (1).



Figure S3. HSQC (400 MHz, CDCl₃) spectrum of asnovolin A (1).



Figure S4. HMBC (400 MHz, $CDCI_3$) spectrum of asnovolin A (1).



Figure S5. ¹H-¹H COSY (400 MHz, $CDCI_3$) spectrum of asnovolin A (**1**).



Figure S6. NOESY (400 MHz, CDCl₃) spectrum of asnovolin A (**1**).



Figure S7. ¹H NMR (400 MHz, CDCl₃) spectrum of asnovolin B (**2**).



Figure S8. ¹³C NMR (100 MHz, $CDCl_3$) spectrum of asnovolin B (**2**).



Figure S9. HSQC (400 MHz, CDCl₃) spectrum of asnovolin B (2).



Figure S10. HMBC (400 MHz, CDCl₃) spectrum of asnovolin B (2).



Figure S11. ¹H-¹H COSY (400 MHz, CDCl₃) spectrum of asnovolin B (**2**).



Figure S12. NOE (500 MHz, CDCl₃) spectrum of asnovolin B (**2**). Irradiation to H-2a (a), H-2b (b), H-5 (c), H-6b (d), H-11a (e), H-13 (f), H-5' (g), H-6' (h) and H-7'b (i).



Figure S13. ¹H NMR (400 MHz, CDCl₃) spectrum of asnovolin C (**3**).



Figure S14. ¹³C NMR (100 MHz, $CDCI_3$) spectrum of asnovolin C (3).



Figure S15. HSQC (400 MHz, $CDCI_3$) spectrum of asnovolin C (3).



Figure S16. HMBC (400 MHz, $CDCI_3$) spectrum of asnovolin C (3).



Figure S17. ¹H-¹H COSY (400 MHz, $CDCI_3$) spectrum of asnovolin C (3).





Figure S19. ¹H NMR (400 MHz, CDCl₃) spectrum of asnovolin D (**4**).



Figure S20. ¹³C NMR (100 MHz, $CDCI_3$) spectrum of asnovolin D (4).



Figure S21. HSQC (400 MHz, $CDCI_3$) spectrum of asnovolin D (4).



Figure S22. HMBC (400 MHz, CDCl₃) spectrum of asnovolin D (4).



Figure S23. $^{1}H^{-1}H$ COSY (400 MHz, CDCl₃) spectrum of asnovolin D (4).



Figure S24. NOESY (400 MHz, $CDCl_3$) spectrum of asnovolin D (4).



Figure S25. ¹H NMR (400 MHz, $CDCI_3$) spectrum of asnovolin E (5).



Figure S26. ¹³C NMR (100 MHz, $CDCl_3$) spectrum of asnovolin E (5).



Figure S27. HSQC (400 MHz, $CDCl_3$) spectrum of asnovolin E (5).



Figure S28. HMBC (400 MHz, CDCl₃) spectrum of asnovolin E (5).



Figure S29. ¹H-¹H COSY (400 MHz, $CDCI_3$) spectrum of asnovolin E (5).



Figure S30. NOESY (400 MHz, $CDCl_3$) spectrum of asnovolin E (5).



Figure S31. ¹H NMR (400 MHz, CDCl₃) spectrum of asnovolin F (6).



Figure S32. ¹³C NMR (100 MHz, $CDCl_3$) spectrum of asnovolin F (6).



Figure S33. HSQC (400 MHz, $CDCI_3$) spectrum of asnovolin F (6).



Figure S34. HMBC (400 MHz, $CDCI_3$) spectrum of asnovolin F (6).



Figure S35. ¹H-¹H COSY (400 MHz, $CDCl_3$) spectrum of asnovolin F (**6**).



Figure S36. NOESY (400 MHz, $CDCI_3$) spectrum of asnovolin F (6).



Figure S37. ¹H NMR (400 MHz, $CDCl_3$) spectrum of asnovolin G (7).



Figure S38. ¹³C NMR (100 MHz, CDCl₃) spectrum of asnovolin G (7).



Figure S39. HSQC (400 MHz, $CDCl_3$) spectrum of asnovolin G (7).



Figure S40. HMBC (400 MHz, $CDCl_3$) spectrum of asnovolin G (7).



Figure S41. ¹H-¹H COSY (400 MHz, CDCl₃) spectrum of asnovolin G (7).



Figure S42. NOESY (400 MHz, $CDCl_3$) spectrum of asnovolin G (7).



Figure S43. Comparison of CD spectrums of asnovolins A-E (1–5) in MeOH. 1 (blue), 2 (red), 3 (pink), 4 (green) and 5 (black).



Figure S44. Key 2D-NMR correlations for asnovolins B, D, E and G (2, 4, 5 and 7)



Figure S45. Key NOESY correlations of asnovolins B, D, E and G (2, 4, 5 and 7)



Figure S46. Putative biosynthesis pathway of asnovolins.